Portal de Periódicos da CAPES

Immunomagnetic Quantification of Circulating Tumor Cells as a Prognostic Factor of Androgen Deprivation Responsiveness in Patients With Hormone Naive Metastatic Prostate Cancer

2008; Lippincott Williams & Wilkins; Volume: 180; Issue: 4 Linguagem: Inglês

10.1016/j.juro.2008.06.021

1527-3792

Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara,

Radiation Therapy and Dosimetry

No AccessJournal of UrologyAdult Urology1 Oct 2008Immunomagnetic Quantification of Circulating Tumor Cells as a Prognostic Factor of Androgen Deprivation Responsiveness in Patients With Hormone Naive Metastatic Prostate Canceris accompanied byWAVE1 is Associated With Invasiveness and Growth of Prostate Cancer Cells Takatsugu Okegawa, Kikuo Nutahara, and Eiji Higashihara Takatsugu OkegawaTakatsugu Okegawa , Kikuo NutaharaKikuo Nutahara , and Eiji HigashiharaEiji Higashihara View All Author Informationhttps://doi.org/10.1016/j.juro.2008.06.021AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determined whether circulating tumor cells predict prostate specific antigen failure in patients with metastatic prostate cancer before endocrine therapy and compared their prognostic ability with other clinical factors. Materials and Methods: Circulating tumor cells were enumerated with the CellSearch™ system in whole blood. This system was developed using epithelial cell adhesion molecule antibody based immunomagnetic capture and automated staining methodology. Prostate cancer cell lines (PC3, LNCaP, DU145) and mixed blood from healthy men were analyzed using this system. Blood samples from 80 patients with metastatic prostate cancer before endocrine therapy were analyzed. Circulating tumor cells were then assessed every 3 months after endocrine therapy in these patients. Results: Circulating tumor cell assay accuracy and reliability were determined using prostate cancer cell line (PC3, LNCaP, DU145) spiking experiments, which demonstrated a strong linear correlation (r = 0.99) and a constant recovery rate of 69% ± 3%, 95% ± 3% and 89% ± 2%, respectively. The number of circulating tumor cells found ranged from 0 to 222 per 7.5 ml blood (mean 17 ± 31, median 14). A threshold of 5 or more circulating tumor cells per 7.5 ml blood was used to evaluate the ability of circulating tumor cells to predict androgen deprivation responsiveness. Of the 80 patients 44 (55%) had 5 or more circulating tumor cells with a median androgen deprivation responsiveness of 17 months compared to more than 32 months for those with fewer than 5 circulating tumor cells (p = 0.007). The presence of circulating tumor cells, nadir prostate specific antigen values and Gleason score were significant parameters predictive of androgen deprivation responsiveness on univariate and multivariate analyses. Conclusions: In this study the presence of 5 or more circulating tumor cells in 7.5 ml blood was associated with androgen deprivation responsiveness in patients with metastatic prostate cancer before endocrine therapy. References 1 : Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia2004; 6: 2004. Google Scholar 2 : Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate2000; 44: 210. Google Scholar 3 : Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem2005; 51: 1538. Google Scholar 4 : Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem2004; 50: 826. Google Scholar 5 : Quantitative reverse transcription-PCR assay with an internal standard for the detection of prostate-specific antigen mRNA. Clin Chem1999; 45: 1397. Google Scholar 6 : Quantitative PSA RT-PCR for preoperative staging of prostate cancer. Prostate2003; 56: 263. Google Scholar 7 : Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology2001; 58: 386. Google Scholar 8 : A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay2002; 25: 104. Google Scholar 9 : Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med2004; 351: 781. Google Scholar 10 : Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol2005; 23: 1420. Google Scholar 11 : Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology2005; 65: 713. Google Scholar 12 : Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer1998; 61: 195. Google Scholar 13 : Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol2006; 24: 3984. Google Scholar 14 : Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int2007; 99: 519. Google Scholar 15 : Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol1993; 11: 607. Google Scholar 16 : Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology2003; 61: 277. Google Scholar 17 : Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. Semin Surg Oncol2001; 20: 304. Google Scholar 18 : Detectable tumor cells in the blood and bone marrow: smoke or fire?. Cancer1998; 83: 394. Google Scholar Department of Urology, The University of Kyorin, Mitaka, Tokyo, Japan© 2008 by American Urological AssociationFiguresReferencesRelatedDetailsCited byOkegawa T, Nutahara K and Higashihara E (2018) Prognostic Significance of Circulating Tumor Cells in Patients With Hormone Refractory Prostate CancerJournal of Urology, VOL. 181, NO. 3, (1091-1097), Online publication date: 1-Mar-2009.Related articlesJournal of Urology19 Aug 2008WAVE1 is Associated With Invasiveness and Growth of Prostate Cancer Cells Volume 180Issue 4October 2008Page: 1342-1347 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordsprostatic neoplasmsprostate-specific antigenneoplasm metastasisneoplasm circulating cellsMetricsAuthor Information Takatsugu Okegawa More articles by this author Kikuo Nutahara More articles by this author Eiji Higashihara More articles by this author Expand All Advertisement PDF downloadLoading ...